Neurocrine Biosciences, Inc.
NBIXNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 16, 2026 close
- Market cap
- $14.27B
- P/E (TTM)
- 20.23
- Forward P/E
- 10.04
- Dividend yield
- -
- 52-week range
- $122.14$186.12
- Volume (live)
- -
- Avg. volume (3M)
- 1.34M
Neurocrine Biosciences (NBIX) Stock Price & Financial Analysis
Neurocrine Biosciences Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $135.55 - $138.20 |
|---|---|
| 52-Week High | $186.12 |
| 52-Week Low | $122.14 |
| Open | $137.86 |
| Volume (last close) | 1.13M |
| Average Volume (3M) | 1.34M |
| Revenue (TTM) | 3.37B |
|---|---|
| Net Income (TTM) | 705.50M |
| Free Cash Flow (TTM) | 870.40M |
| EPS (TTM) | $6.82 |
| Profit Margin | 20.91% |
| Operating Margin | 23.85% |
| Return on Equity (ROE) | 19.10% |
| Debt to Equity | 0.11 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 14.27B |
|---|---|
| Shares Outstanding | 104.20M |
| P/E Ratio (TTM) | 20.23 |
| Forward P/E | 10.04 |
| Price to Sales (P/S) | 4.23 |
| Price to Book (P/B) | 3.86 |
| EV/EBITDA | 15.70 |
| 50-Day MA | $150.23 |
|---|---|
| 200-Day MA | $147.10 |
| 1-Year Change | −2.24% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Neurocrine Biosciences at a Glance
As of the Oct 16, 2026 close, Neurocrine Biosciences (NBIX) has a market capitalization of $14.27B. The stock trades at 20.2× trailing earnings, 10.0× forward earnings and 4.2× sales. Over the trailing twelve months it earned $705.50M on revenue of $3.37B (a 20.9% profit margin) and generated $870.40M of free cash flow. Revenue grew 34.4% year over year.
As of its latest reported balance sheet, it holds $332.40M in cash and securities against $401.80M of debt, a net debt position of $69.40M.
Neurocrine Biosciences does not currently pay a dividend.
The share price is down 2.2% over the past year. At $135.77 (the Oct 16, 2026 close) it sits within its 52-week range of $122.14 to $186.12, below its 200-day moving average of $147.10.
Based on 32 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $209.04, 54.0% above the Oct 16, 2026 close.
Frequently Asked Questions About Neurocrine Biosciences
What is the current stock price for NBIX?
As of the Oct 16, 2026 close, NBIX stock trades at $135.77. The 52-week range is $122.14–$186.12, with a day range of $135.55–$138.20.
What is the P/E ratio for NBIX?
As of the Oct 16, 2026 close, Neurocrine Biosciences's trailing twelve-month (TTM) P/E ratio is 20.2, meaning investors pay $20.2 for every $1 of annual earnings. The forward P/E is 10.0, reflecting analyst expectations for future earnings. Neurocrine Biosciences operates in the Healthcare sector.
Does NBIX pay dividends?
Neurocrine Biosciences does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for NBIX?
Based on ratings from 32 professional analysts over the last 90 days, the consensus for NBIX is Buy. The average 12-month price target is $209.04, a 54.0% upside from the Oct 16, 2026 close of $135.77.
What is the market cap of NBIX?
As of the Oct 16, 2026 close, Neurocrine Biosciences's market capitalization is $14.15B, classifying it as a large-cap company. Neurocrine Biosciences operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.